On October 25-27 2025 Breakthrough T1D gathered leading experts from academia, biotech and pharma to discuss how disease-modifying therapies can change the course of type 1 diabetes from the earliest stages. This recording from one of the panel session highlighted progress from Stage 2 treatments like teplizumab toward new applications in Stage 3, as well as next-generation immunotherapies from Sanofi, Eli Lilly and Diamyd Medical targeting different immune pathways and specific genetic subgroups. A central theme was the need to treat T1D as an autoimmune disease, not only a glucose/insulin problem, and to secure regulatory acceptance of C-peptide as a key endpoint, while also addressing two urgent challenges: scaling up screening for at-risk individuals in stages 1–2, and speeding clinical trial recruitment and regulatory pathways so that effective therapies reach patients earlier and more widely.

Panel participants: Michael Haller, Professor of Pediatrics, University of Florida; Michelle Katz, Pediatric Endocrinologist, Eli Lilly; Monica Kumar, Senior Global Project Head, Sanofi; Anton Lindqvist, Chief Scientific Officer, Diamyd Medical. Moderated by Sanjoy Dutta, Ph.D., Breakthrough T1D’s Chief Scientific Officer.